Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan

Am J Clin Nutr. 1992 Nov;56(5):863-7. doi: 10.1093/ajcn/56.5.863.

Abstract

Previous observations have shown that oral administration of 5-hydroxytryptophan (5-HTP) without dietary prescriptions causes anorexia, decreased food intake, and weight loss in obese subjects. To confirm these data over a longer period of observation and to verify whether adherence to dietary restriction could be improved by 5-HTP, 20 obese patients were randomly assigned to receive either 5-HTP (900 mg/d) or a placebo. The study was double-blinded and was for two consecutive 6-wk periods. No diet was prescribed during the first period, a 5040-kJ/d diet was recommended for the second. Significant weight loss was observed in 5-HTP-treated patients during both periods. A reduction in carbohydrate intake and a consistent presence of early satiety were also found. These findings together with the good tolerance observed suggest that 5-HTP may be safely used to treat obesity.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • 5-Hydroxytryptophan / therapeutic use*
  • Adult
  • Dietary Carbohydrates / administration & dosage
  • Dietary Proteins / administration & dosage
  • Energy Intake
  • Female
  • Humans
  • Hydroxyindoleacetic Acid / urine
  • Hyperphagia / drug therapy*
  • Obesity / diet therapy
  • Obesity / drug therapy*
  • Weight Loss

Substances

  • Dietary Carbohydrates
  • Dietary Proteins
  • Hydroxyindoleacetic Acid
  • 5-Hydroxytryptophan